<code id='2BFBA25865'></code><style id='2BFBA25865'></style>
    • <acronym id='2BFBA25865'></acronym>
      <center id='2BFBA25865'><center id='2BFBA25865'><tfoot id='2BFBA25865'></tfoot></center><abbr id='2BFBA25865'><dir id='2BFBA25865'><tfoot id='2BFBA25865'></tfoot><noframes id='2BFBA25865'>

    • <optgroup id='2BFBA25865'><strike id='2BFBA25865'><sup id='2BFBA25865'></sup></strike><code id='2BFBA25865'></code></optgroup>
        1. <b id='2BFBA25865'><label id='2BFBA25865'><select id='2BFBA25865'><dt id='2BFBA25865'><span id='2BFBA25865'></span></dt></select></label></b><u id='2BFBA25865'></u>
          <i id='2BFBA25865'><strike id='2BFBA25865'><tt id='2BFBA25865'><pre id='2BFBA25865'></pre></tt></strike></i>

          
          WSS
          Courtesy Sanofi

          LONDON — In a bid to expand its pipeline of inflammation-targeting drugs, Sanofi said Tuesday it was acquiring California-based Inhibrx in a deal worth up to $2.2 billion.

          The core of the deal is Inhibrx’s experimental therapy for AATD, a disease that progressively damages the lungs and liver. The medicine, INBRX-101, is designed to reduce inflammation and stave off further damage to the tissue. Inhibrx has completed Phase 1 testing of the drug and is enrolling patients in a Phase 2 trial.   

          advertisement

          Inhibrx’s other drug candidates, including its line of cancer-targeting immunotherapies, will be portioned out into a new company that will continue to be called Inhibrx. Mark Lappe, the founder and CEO of Inhibrx, will lead the spun-out company. 

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In

          Leave your comment

          Please enter your name
          Please enter your comment

          fashion